|
GUF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.03750000005165E-06 |
| Normal-vs-Stage3 |
8.21565038222616E-15 |
| Normal-vs-Stage4 |
1.62669877568078E-12 |
| Stage1-vs-Stage2 |
5.938400E-02 |
| Stage1-vs-Stage3 |
9.775200E-01 |
| Stage1-vs-Stage4 |
1.098960E-01 |
| Stage2-vs-Stage3 |
6.251800E-02 |
| Stage2-vs-Stage4 |
7.399000E-03 |
| Stage3-vs-Stage4 |
1.748820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.14340000001434E-06 |
| Normal-vs-Asian |
2.48379999900905E-08 |
| Caucasian-vs-AfricanAmerican |
1.322000E-01 |
| Caucasian-vs-Asian |
4.254400E-02 |
| AfricanAmerican-vs-Asian |
9.759600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.55351295663786E-15 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
5.713600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.03590003242005E-09 |
| Normal-vs-Age(81-100Yrs) |
9.051800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.779000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.847520E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.165800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.482110E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.197800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.837400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.452230E-01 |
| Classical-VS-Follicular |
6.960000E-04 |
| Classical-VS-Other |
6.328000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.007710E-04 |
| Tall-VS-Other |
7.623000E-01 |
| Tall-VS-Normal |
1.76048065014811E-12 |
| Follicular-VS-Other |
1.483200E-01 |
| Follicular-VS-Normal |
5.01229999949615E-07 |
| Other-VS-Normal |
3.78010000000595E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.30451205393456E-13 |
| Normal-vs-N1 |
1.55431223447522E-15 |
| N0-vs-N1 |
2.562400E-02 |
|
|
